Cancer Biology  

Biography

Dr. Geetha S, a dedicated researcher at the Center for Global Health Research, Saveetha Medical College and Hospital, is a highly motivated individual who is constantly seeking new knowledge and ways to enhance her research methods. Passionate about uncovering novel approaches to combat cancer, her current research focuses on cancer biology, particularly in signaling pathways. She is committed to studying the underlying mechanisms of the tumor microenvironment and developing new treatments and therapeutic strategies. Dr. Geetha has published over 25 peer-reviewed articles in esteemed international journals.

Education:

  • Ph.D., Biotechnology - SRM Institute of Science and Technology, Chengalpattu, India (June 2020 – January 2024).

  • M.Sc., Genomics - Madurai Kamaraj University Madurai, Tamil Nadu, India (Jun 2014 – May 2016).

  • B.Sc. Biotechnology - Lady Doak College Madurai, Tamil Nadu, India (Jun 2011 – May 2014).

Key research areas:

  • Understanding the intricate cellular signaling pathways within cancer stem cells and its molecular mechanism with other cell types

  • Explore the dynamic interplay between tumor microenvironment components and cancer progression

  • Advancement of strategies that leverage the tumor microenvironment for more effective and personalized cancer interventions

Recent Publications:

  1. Shanmugam, G, Subramaniyam, K., George, M., & Sarkar, K. (2023). HDAC inhibition regulates oxidative stress in CD4 + Thelper cells of chronic obstructive pulmonary disease and non-small cell lung cancer patients via mitochondrial transcription factor a (mtTFA) modulating NF-κB/HIF1α axis. International immunopharmacology, 122, 110661. https://doi.org/10.1016/j.intimp.2023.110661. (IF: 5.6).

  2. Shanmugam, G, Sunny, J. S., Rakshit, S., George, M., Leela, K. V., Sarkar, K. (2022). Involvement of inflammatory cytokines and epigenetic modification of the mtTFA complex in T-helper cells of patients' suffering from non-small cell lung cancer and chronic obstructive pulmonary disease. Molecular immunology, 151, 70–83. https://doi.org/10.1016/j.molimm.2022.08.006. (IF: 3.6).

  3. Shanmugam, G., Rakshit, S., Sarkar, K. (2022). HDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases. Translational oncology, 16, 101312. https://doi.org/10.1016/j.tranon.2021.101312. (IF : 5.0).

  4. Shanmugam, G, Das, S., Paul, S., Rakshit, S., Sarkar, K. (2022). Clinical relevance and therapeutic aspects of professional antigen-presenting cells in lung cancer. Medical oncology, 39(12), 237. https://doi.org/10.1007/s12032-022-01841-6. (IF: 3.4).

  5. Shanmugam, G., Mohan, A., Kumari, K., Louis, J. M., Soumya Krishnan, U., Balagopal, P. G., George, N. A., Sebastian, P., & Maliekal, T. T. (2019). A novel reporter construct for screening small molecule inhibitors that specifically target self-renewing cancer cells. Experimental cell research, 383(2), 111551. https://doi.org/10.1016/j.yexcr.2019.111551. (IF: 3.7).

  6. Jill, N., Bhootra, S., Kannanthodi, S., Shanmugam, G., Rakshit, S., Rajak, R., Thakkar, V., & Sarkar, K. (2023). Interplay between signal transducers and activators of transcription (STAT) proteins and cancer: involvement, therapeutic and prognostic perspective. Clinical and experimental medicine, 10.1007/s10238-023-01198-8. Advance online publication. https://doi.org/10.1007/s10238-023-01198-8. (IF: 4.6).

  7. Mukherjee, O., Rakshit, S., Shanmugan, G., & Sarkar, K. (2023). Natural Plant Products Mediated Prevention of Cancer Facilitated through Immune Suppression of Treg Cells. Current topics in medicinal chemistry, 10.2174/0115680266275768231027100120. Advance online publication. https://doi.org/10.2174/0115680266275768231027100120. (IF: 3.5).

  8. Mukherjee, O., Rakshit, S., Shanmugam, G., & Sarkar, K. (2023). Role of chemotherapeutic drugs in immunomodulation of cancer. Current research in immunology, 4, 100068. https://doi.org/10.1016/j.crimmu.2023.100068. (IF: 0.5).

  9. Bhootra, S., Jill, N., Shanmugam, G, Rakshit, S., Sarkar, K. (2023). DNA methylation and Cancer: Transcriptional regulation, prognostic and therapeutic perspective. Medical Oncology, 40(2):71. doi: 10.1007/s12032-022-01943-1. (IF: 3.4).

  10. Bhootra, S., Jill, N., Rajak, R., Shanmugam, G., Rakshit, S., Kannanthodi, S., Thakkar, V., George, M., & Sarkar, K. (2023). Diospyros malabarica fruit preparation mediates immunotherapeutic modulation and epigenetic regulation to evoke protection against non-small cell lung cancer (NSCLC). Journal of ethnopharmacology, 314, 116525. (IF: 5.1)